Want to see SABS full AI Analyst Report?
SABS Stock Chart & Stats
$3.51
-$0.07(-1.99%)
At close: 4:00 PM EDT
$3.51
-$0.07(-1.99%)
Day’s Range― - ―
52-Week Range$1.85 - $5.15
Previous Close$3.44
Volume609.58K
Average Volume (3M)398.22K
Market Cap
$329.37M
Enterprise Value$213.54
Total Cash (Recent Filing)$102.63M
Total Debt (Recent Filing)$5.13M
Price to Earnings (P/E)2.9
Beta0.96
Next Earnings
Nov 17, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.24
Shares Outstanding90,986,370
10 Day Avg. Volume357,955
30 Day Avg. Volume398,221
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)0.48
Price to Sales (P/S)0.00
P/FCF Ratio-1.58
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.14Price Target Upside245.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.2
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Antibody PlatformSAB’s Tc bovine platform is a differentiated technology base for generating fully human polyclonal antibodies. If validated clinically, it can support multiple programs and partnerships, creating platform-level opportunity beyond any single candidate.
SAB-142 Trial ExpansionThe grant-backed PRISE-hATG study broadens SAB-142 evaluation beyond newly diagnosed patients and is harmonized with the Phase 2b SAFEGUARD study. This may expand the addressable population and improve evidence across patient cohorts.
Low Financial LeverageVery low debt and a larger equity base provide greater balance-sheet flexibility than a highly leveraged biotech. This can help SAB fund development activities and negotiate partnerships without excessive interest or repayment pressure.
Bears Say
Revenue CollapseThe collapse to effectively zero revenue shows that SAB lacks dependable commercial or partnership revenue at present. Without recovery through collaborations, grants, or product approvals, the company remains dependent on external funding and future clinical success.
Persistent Cash BurnSustained negative operating and free cash flow indicates that current activities consume substantial capital without internally funding development. Continued burn increases reliance on financing, partnerships, or spending reductions and may constrain the pace of clinical progress.
Weak Operating ProfitabilityLarge operating losses and negative gross profit demonstrate that the business has not yet established sustainable unit economics. Positive net income in 2025 was not supported by revenue recovery or cash generation, reducing confidence in recurring earnings quality.
SAB Biotherapeutics News
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $1.85 and its highest was $5.15 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
SAB Biotherapeutics’s market cap is $329.37M.
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 83 days.
How were SAB Biotherapeutics’s earnings last quarter?
SAB Biotherapeutics released its earnings results on Aug 06, 2026. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.283 by $0.003.
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate is -0.28.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 90,986,370 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
SAB Biotherapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.283. Following the earnings report the stock price went up 2.122%.
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Currently, no hedge funds are holding shares in SABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SAB Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.14 (245.95% Upside)
$12.14 (245.95% Upside)
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.5%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
690.62%
Trailing 12-Months
Company Description
SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
SABS Earnings Call
Q2 2026
0:00 / 0:00
SABS Stock 12 Month Forecast
Average Price Target
$12.14
▲(245.95% Upside)
Technical Analysis
Ownership Overview
14.61% Insiders
2.86% Mutual Funds
51.79% Other Institutional Investors
25.04% Public Companies and
Individual Investors